Inmune Bio, Inc. - 10-Q Filing
Inmune Bio reported a net loss of $5.4 million for Q1 2026, compared to a $9.7 million loss in Q1 2025. The company's operating expenses totaled $5.8 million, driven by $2.2 million in general and administrative costs and $3.6 million in research and development expenses. Cash and cash equivalents decreased to $21.4 million as of March 31, 2026, from $24.8 million at the end of 2025.
Tickers: $INMB